GLP-1 Analogs Activate AMP Kinase Leading to Reversal of the Warburg Effect in Breast Cancer Cells
Ligumsky H, Amir S, Arbel Rubinstein T, et al.
Summary
GLP-1 receptor agonists were shown to activate AMP kinase and reverse the Warburg metabolic switch in breast cancer cells, suggesting potential anti-cancer metabolic effects.
Clinical Significance
Emerging evidence suggests GLP-1 RAs may have metabolic effects relevant to cancer biology, beyond their established cardiovascular and weight loss benefits.
Study Overview
This in vitro study investigated the metabolic effects of GLP-1 receptor agonists on breast cancer cells, specifically examining their impact on the Warburg effect (aerobic glycolysis).
Key Findings
Metabolic Effects
- GLP-1 analogs activated AMP-activated protein kinase (AMPK)
- Reversed the Warburg metabolic switch in cancer cells
- Shifted metabolism from glycolysis toward oxidative phosphorylation
Mechanism
- AMPK activation as primary mechanism
- Metabolic reprogramming of cancer cells
- Effects observed across multiple GLP-1 analogs
Limitations
- In vitro study only
- No in vivo or clinical validation yet
- Clinical significance unknown
Clinical Relevance
While preliminary, this research adds to the growing understanding of GLP-1 RAs' metabolic effects beyond glucose control and weight loss.
Source
Relatert forskning
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis evaluated the association between GLP-1 receptor agonist use and de…
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…
Exposure-Adjusted Safety and Efficacy of GLP-1 and GLP-1/GIP Receptor Agonists for Weight Management and Type 2 Diabetes
This comprehensive analysis of FDA regulatory data across 14 medications and over 34,000 safety subj…
Dapagliflozin Combined with Liraglutide vs Monotherapy in Obese Patients with Heart Failure
Combination therapy of dapagliflozin (SGLT2 inhibitor) with liraglutide showed superior outcomes com…